Organic compounds -- part of the class 532-570 series – Organic compounds – Carbohydrates or derivatives
Reexamination Certificate
2007-12-18
2007-12-18
Navarro, Mark (Department: 1645)
Organic compounds -- part of the class 532-570 series
Organic compounds
Carbohydrates or derivatives
C514S04400A
Reexamination Certificate
active
11015578
ABSTRACT:
Polypeptide and polynucleotide vaccines effective to treat or prevent infection of a mammal, such as a dog, a cat, or a human, by a protozoan. Methods of treatment and prevention are also provided, including therapeutic administration of the vaccine to an infected mammal to prevent progression of infection to a chronic debilitating disease state. Preferred embodiments of the polynucleotide vaccine contain nucleotide coding regions that encode polypeptides that are surface-associated or secreted byT. cruzi. Optionally the efficacy of the polynucleotide vaccine is increased by inclusion of a nucleotide coding region encoding a cytokine. Preferred embodiments of the polypeptide vaccine include immunogenic peptides that contain membrane transducing sequences that allow the polypeptides to translocate across a mammalian cell membrane.
REFERENCES:
patent: 5304371 (1994-04-01), Reed
patent: 5646114 (1997-07-01), Lambert et al.
patent: 6875584 (2005-04-01), Tarleton et al.
Armah et al., “S-Myristoylation of a Glycosylphosphatidylinositol-specific Phospholipase C inTrypanosoma brucei,” J. Biol. Chem., 274(9):5931-5938 (Feb. 26, 1999).
Abrahamsohn, “Cytokines in inate and acquired immunity toTrypanosoma cruziinfection,”Braz. J. Med. Biol. Res., 31(1):117-121 (Jan. 1998).
Alberti et al., “Specific cellular and humoral immune response in Balb/c mice immunised with an expression genomic library ofTrypanosoma cruzi,” Vaccine, 16(6):608-612 (Apr. 1998).
Al-Qahtani et al., “A 5′ untranslated region which directs accurate and robust translation by prokaryotic and mammalian ribosomes,”Nuc. Acids Res., 24(6):1173-1174 (1996).
Andrews et al., “Presence of antibodies to the major surfacc glycoprotein ofTrypunosoma cruziamastigotes in ser from chagasic patients,”Am. J. Trop. Med. Hyg., 40(1):46-49 (1989).
Andrews, “The Acid-Active Hemolysin ofTrypansoma cruzi,”Exp. Parasitol., 71:241-244 (1990).
Barry et al., “Protection against mycoplasma infection using expression-library immunization,”Nature, 377(6550):632-635 (1995).
Barry et al., “Biological features of genetic immunization,”Vaccine, 15(8):788-791 (1997).
Basombrio, “Trypanosoma cruzi: Partial Prevention of the Natural Infection of Guinea Pigs with a Killed Parasite Vaccine,”Exp. Parasitol., 71:1-8 (1990).
Bharadwaj et al., “Induction of Protective Immune Responses by Immunization with Linear Multipitope Peptides Based on Conserved Sequences fromPlasmodium falicparumAntigens,”Infect. Immun., 66(7):3232-3241 (Jul. 1998).
Biebinger et al., “A Plasmid Shuttle Vector Bearing an rRNA Promoter is Extrachromosmally Maintained inCrithidia fasciculata,” Exp. Parasitol., 83(2):252-258 (1996).
Bliss et al., “IL-12, as an Adjuvant, Promotes a T Helper 1 Cell, but Does Not Suppress a T Helper 2 Cell Recall Response,”J. Immunol., 156(3):887-894 (1996).
Brener, “Why Vaccines do not work in Chagas Disease,”Parasitol. Today, 2(7):196-197 (1986).
Carpenter et al., “Linearized free maxicircle DNA inCrithidia fasciculatais a product of topoisomerase II-mediated cleavage,”Mol. Biochem. Parasitol., 76:115-123 (1996).
Chow et al., “Development of Th1 and Th2 Populations and the Nature of Immune Responses to Hepatitis B Virus Vaccines Can Be Modulated by Codelivery of Various Cytokine Genes,”J. Immunol., 160(3):1320-1329 (Feb. 1, 1998).
Clayton et al., “Protein Trafficking in Kinetoplacid Protozoa,”Microbiol. Rev., 59(3):325-344 (1995).
Coburn et al., “Stable DNA transfection of a wide range of trypanosomatids,”Mol. Biochem. Parasitol., 46:169-179 (1991).
Conry et al., “Polynucleotide-Mediated Immunization Therapy of Cancer,”Seminars Oncol., 23(1):135-147 (1996).
Costa et al., “Immunization with a plasmid DNA containing the gene oftrans-sialidase reducesTrypanosoma cruziinfection in mice,”Vaccine, 16(8):768-774 (May 1998).
Cross et al., “The SurfaceTrans-Sialidase Family ofTrypansoma cruzi,” Ann. Rev. Microbiol., 47:385-411 (1993).
Denkers et al., “Regulation and Function of T-Cell-Mediated Immunited duringToxoplasma gondiiInfection,” Clin Microbiol Rev. 1998, vol. 11, pp. 569-588.
DeRisi et al., “Use of a cDNA microarray to analyse gene expression patterns in human cancer,” Nature Genet., 14(4):457-460 (1996).
DeRisi et al., “Exploring the Metabolic and Genetic Control of Gene Expression on Genomic Scale,”Science, 278(5338):680-686 (1997).
Donnelly et al., “DNA Vaccines,”Ann. Rev. Immunol., 15:617-648 (1997).
Ellis et al., “New Technologies for Making Vaccines,” Chapter 29, p. 571 second paragraph of book entitled “Vaccines,” Authors: S.A.Plotkin and E.A. Mortimer (with 40 contributors), Published by W.B. Saunders Company (Philadelphia), 1988.
Endresz et al., “Induction of human cytomegalovirus (HCMV)-glycoprotein B (gB)-specific neutralizing antibody and phosphoprotein 65 (pp65)-specific cytotoxic T lymphocyte responses by naked DNA immunization,”Vaccine, 17(1):50-58 (Jan. 1999).
Englund, “The structure and biosynthesis of glycosyl phosphatidylinositol protein anchors,”Annu. Rev. Biochem.62:121-138 (1993).
Freedman et al., “Two more independent selectable markers for stable transfection ofLeishmania,” Mol. Biochem. Parasitol., 62:37-44 (1993).
Fontt et al., “Relationship between granulocyte macrophage-colony stimulating factor, tumour necrosis factor-α andTrypanosoma cruziinfection of murine macrophages,”Parasite Immunol., 17(3):135-141 (1995).
Fontt et al., “Granulocyte-Macrophage Colony-Stimulating Factor: Involvement in Control ofTrypanosoma cruziInfection in Mice,”Infect. Immun., 64(8):3429-3434 (1996).
Fontt et al., “Effects of Granulocyte-Macrophage Colony-Stimulating Factor and Tumor Necrosis Factor Alpha onTrypanosoma cruziTrypomastigotes,”Infect. Immun., 66(6):2722-2727 (Jun. 1998).
Fouts et al., “Nucleotide sequence and transcription of a trypomastigote surface antigen gene ofTrypanosoma cruzi,” Mol. Biochem. Parasitol., 46:189-200 (1991).
Fouts et al., “Trypanosoma cruzitrypomastigote surface glycoprotein (TSA-1) mRNA, GenBank Accession No. M58466,” (1993).
Garg et al., “Protein with Glycosylphosphatidylinositol (GPI) Signal Sequences Have Divergent Fates during a GPI Deficiency,”J. Biol. Chem., 272(19):12482-12491 (1997).
Garg et al., “Delivery byTrypanosoma cruziof Proteins into the MHC Class 1 Antigen Processing and Presentation Pathway,”J. Immunol., 158:3293-3302 (1997).
Garg et al., “Elicitation of protective immunity toTrypanosoma cruziusing DNA vaccines,” Proceedings of the 10thInternational Congress of Immunology, New Delhi, India, Monduzzi, Bologna pp. 1421-1426 (Nov. 1-6, 1998).
Geissler et al., “Enhancement of Cellular and Humoral Immune Responses to Hepatitis C Virus Core Protein Using DNA-Based Vaccines Augmented with Cytokine-Expressing Plasmids,”J. Immunol., 158(3):1231-1237 (1997).
Gomes, “PCR and Sero-Diagnosis of Chronic Chagas' Disease,”Appl. Biochem. Biotechnol., 66(2):107-119 (1997).
Gurunathan et al., “Vaccination with DNA Encoding the Immunodominant LACK Parasite Antigen Confers Protective Immunity to Mice Infected withLeishmania major, ” J. Exp. Mes., 186(7):1137-1147 (1997).
Ha et al., “Use of the green fluorescent protein as a marker in transfectedLeishmania,” Mol. Biochem. Parasitol., 77:57-64 (1996).
Hartikka et al., “An Improved Plasmid DNA Expression Vector for Direct Injection into Skeletal Muscle,”Human Gene Ther., 7(10):1205-1217 (1996).
Higuchi et al., “The Role of Active Myocarditis in the Development of Heart Failure in Chronic Chagas' Disease: A Study Based on Endomyocardial Biopsies,”Clin. Cardiol. 10(11):655-670
Garg Nisha
Tarleton Rick L.
Mueting Raasch & Gebhardt, P.A.
Navarro Mark
University of Georgia Research Foundation Inc.
LandOfFree
Prophylactic and therapeutic immunization against protozoan... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Prophylactic and therapeutic immunization against protozoan..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Prophylactic and therapeutic immunization against protozoan... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3826577